CRISPR Therapeutics AG (CRSP) EBT (2015 - 2026)

CRISPR Therapeutics AG has disclosed EBT across 12 years of filings, most recently posting -$90.2 million for Q2 2026.

• In Q2 2026, EBT rose 56.48% year-over-year to -$90.2 million; the TTM figure through Jun 2026 stood at -$480.6 million (up 4.83% YoY), while the FY2025 annual figure was -$610.5 million, down 51.15% from the prior year.
• EBT came in at -$90.2 million for Q2 2026 at CRISPR Therapeutics AG, up from -$122.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $59.2 million in Q4 2023 to a low of -$207.3 million in Q2 2025.
• Average EBT over 5 years is -$114.4 million, with a median of -$118.6 million recorded in 2022.
• Year-over-year, EBT soared 148.79% in 2023 and slumped 231.44% in 2024.
• Over 5 years, EBT stood at -$121.4 million in 2022, then soared by 148.79% to $59.2 million in 2023, then tumbled by 231.44% to -$77.8 million in 2024, then plunged by 108.79% to -$162.5 million in 2025, then soared by 44.5% to -$90.2 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$90.2 million in Q2 2026, -$122.1 million in Q1 2026, and -$162.5 million in Q4 2025.